Why Test for EGFR

EGFR testing is important for several reasons:

Targeted therapy selection: EGFR mutations are predictive biomarkers for targeted therapy with EGFR tyrosine kinase inhibitors (TKIs). TKIs are drugs that specifically target and inhibit the activity of the EGFR protein, thereby blocking the growth and survival of cancer cells. EGFR testing helps identify patients who are likely to benefit from these targeted therapies, which can lead to improved outcomes and reduced side effects compared to traditional chemotherapy.

Treatment monitoring: Serial EGFR testing can be used to monitor the effectiveness of EGFR-targeted therapy and detect the emergence of resistance mutations over time. This allows clinicians to adjust the treatment plan accordingly, ensuring patients continue to receive the most appropriate and effective therapy.

Prognostic and predictive information: EGFR mutation status can provide prognostic information about the likely course and aggressiveness of the cancer. Certain EGFR mutations are associated with more aggressive disease and poorer prognosis. This information can help guide treatment decisions and provide patients with a better understanding of their prognosis.

Identification of potential clinical trial opportunities: Patients with EGFR-mutated cancers may be eligible to participate in clinical trials evaluating novel EGFR-targeted therapies or combination therapies. Clinical trials offer the opportunity to access cutting-edge treatments and contribute to the advancement of cancer research.

Overall, EGFR testing is a valuable tool in personalized cancer care, enabling the selection of targeted therapies, monitoring of treatment response, and providing prognostic information for patients with EGFR-mutated lung cancer.